Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Cerevance to Present Positive Phase 2 Solengepras Data in Parkinson’s Disease at the American Academy of Neurology 2026 Annual Meeting

Cerevance has announced promising results from two Phase 2 trials evaluating Solengepras, a novel, once-daily oral GPR6 inhibitor aimed at treating Parkinson’s disease. The trials demonstrated significant reductions in daily OFF time and improvements in sleep-related symptoms, highlighting a non-dopaminergic approach that could address critical unmet needs in this patient population. Presentations at the upcoming American Academy of Neurology (AAN) 2026 Annual Meeting will detail these findings, with key contributions from experts such as Dr. Robert Hauser and Dr. Harini Sarva.

The significance of Solengepras lies in its mechanism of action, which selectively modulates the GPR6 receptor to restore motor and non-motor functions without directly affecting dopamine levels. This is particularly important given the limitations of current dopaminergic therapies, which are associated with side effects like dyskinesias and motor fluctuations. The ongoing Phase 3 ARISE trial aims to further assess the efficacy and safety of Solengepras as an adjunctive therapy to levodopa in patients experiencing significant OFF time, with a focus on both motor and non-motor symptoms, cognitive function, and overall quality of life.

The implications of these findings are substantial for the field of neurodegenerative research. If successful, Solengepras could shift the therapeutic landscape for Parkinson’s disease, offering a first-in-class, non-dopaminergic treatment option that mitigates the side effects commonly associated with traditional therapies. This could accelerate the development of similar non-dopaminergic strategies, potentially leading to new avenues in the management of Parkinson’s disease and other neurodegenerative disorders.

Source: globenewswire.com